Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -21.16 Million EUR | -206.65% |
| 2022 | -6.9 Million EUR | 73.77% |
| 2021 | -26.3 Million EUR | -12.79% |
| 2020 | -23.32 Million EUR | -25.38% |
| 2019 | -18.6 Million EUR | -344.29% |
| 2018 | 7.61 Million EUR | 189.05% |
| 2017 | -8.55 Million EUR | -8.35% |
| 2016 | -7.89 Million EUR | -162.87% |
| 2015 | 12.55 Million EUR | 160.6% |
| 2014 | -20.71 Million EUR | -382.53% |
| 2013 | -4.29 Million EUR | 28.39% |
| 2012 | -5.99 Million EUR | 7.11% |
| 2011 | -6.45 Million EUR | -36.42% |
| 2010 | -4.73 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.94 Million EUR | 0.0% |
| 2023 Q2 | -9.39 Million EUR | -100.0% |
| 2023 Q3 | -5.88 Million EUR | 37.34% |
| 2023 Q4 | -11.77 Million EUR | -100.0% |
| 2023 Q1 | -4.69 Million EUR | 57.89% |
| 2023 FY | -21.16 Million EUR | -206.65% |
| 2022 Q1 | 2.12 Million EUR | 117.5% |
| 2022 Q2 | 4.25 Million EUR | 100.0% |
| 2022 Q3 | -5.57 Million EUR | -231.15% |
| 2022 Q4 | -11.15 Million EUR | -100.0% |
| 2022 FY | -6.9 Million EUR | 73.77% |
| 2021 Q1 | -5.3 Million EUR | 53.44% |
| 2021 Q3 | -6.07 Million EUR | 42.71% |
| 2021 Q4 | -12.15 Million EUR | -100.0% |
| 2021 FY | -26.3 Million EUR | -12.79% |
| 2021 Q2 | -10.6 Million EUR | -100.0% |
| 2020 FY | -23.32 Million EUR | -25.38% |
| 2020 Q1 | -5.96 Million EUR | -6.4% |
| 2020 Q2 | -11.93 Million EUR | -100.0% |
| 2020 Q4 | -11.38 Million EUR | -100.0% |
| 2020 Q3 | -5.69 Million EUR | 52.3% |
| 2019 Q2 | -12.99 Million EUR | -100.0% |
| 2019 FY | -18.6 Million EUR | -344.29% |
| 2019 Q4 | -5.6 Million EUR | -100.0% |
| 2019 Q3 | -2.8 Million EUR | 78.42% |
| 2019 Q1 | -6.49 Million EUR | -329.7% |
| 2018 Q1 | 5.31 Million EUR | 168.2% |
| 2018 Q4 | -1.51 Million EUR | 0.0% |
| 2018 FY | 7.61 Million EUR | 189.05% |
| 2018 Q3 | -1.51 Million EUR | -128.42% |
| 2018 Q2 | 5.31 Million EUR | 0.0% |
| 2017 FY | -8.55 Million EUR | -8.35% |
| 2017 Q4 | -7.8 Million EUR | 0.0% |
| 2017 Q3 | -7.8 Million EUR | -321.28% |
| 2017 Q2 | 3.52 Million EUR | 0.0% |
| 2017 Q1 | 3.52 Million EUR | 289.98% |
| 2016 Q2 | -2.09 Million EUR | 0.0% |
| 2016 Q3 | -1.85 Million EUR | 11.24% |
| 2016 Q1 | -2.09 Million EUR | -171.67% |
| 2016 Q4 | -1.85 Million EUR | 0.0% |
| 2016 FY | -7.89 Million EUR | -162.87% |
| 2015 Q4 | 2.91 Million EUR | 0.0% |
| 2015 FY | 12.55 Million EUR | 160.6% |
| 2015 Q3 | 2.91 Million EUR | -13.17% |
| 2015 Q2 | 3.35 Million EUR | 0.0% |
| 2015 Q1 | 3.35 Million EUR | 144.29% |
| 2014 Q1 | -2.77 Million EUR | -1785.41% |
| 2014 Q3 | -7.58 Million EUR | -173.58% |
| 2014 Q4 | -7.58 Million EUR | 0.0% |
| 2014 FY | -20.71 Million EUR | -382.53% |
| 2014 Q2 | -2.77 Million EUR | 0.0% |
| 2013 Q1 | -2.31 Million EUR | -8.86% |
| 2013 Q2 | -2.31 Million EUR | 0.0% |
| 2013 Q3 | 164.5 Thousand EUR | 107.12% |
| 2013 Q4 | 164.5 Thousand EUR | 0.0% |
| 2013 FY | -4.29 Million EUR | 28.39% |
| 2012 FY | -5.99 Million EUR | 7.11% |
| 2012 Q4 | -2.12 Million EUR | 0.0% |
| 2012 Q3 | -2.12 Million EUR | 0.0% |
| 2011 FY | -6.45 Million EUR | -36.42% |
| 2010 FY | -4.73 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -501.535% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 85.676% |
| Aelis Farma SA | -5.07 Million EUR | -316.739% |
| Biophytis S.A. | -17.02 Million EUR | -24.292% |
| Advicenne S.A. | -7.03 Million EUR | -200.981% |
| genOway Société anonyme | 1.56 Million EUR | 1449.983% |
| IntegraGen SA | -171.39 Thousand EUR | -12246.63% |
| Medesis Pharma S.A. | -3.95 Million EUR | -434.463% |
| Neovacs S.A. | -8.74 Million EUR | -142.033% |
| NFL Biosciences SA | -3.74 Million EUR | -465.002% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 26830.16% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -567.372% |
| Sensorion SA | -22.06 Million EUR | 4.086% |
| Theranexus Société Anonyme | -6.82 Million EUR | -209.932% |
| TME Pharma N.V. | -6.73 Million EUR | -214.163% |
| Valbiotis SA | -7.36 Million EUR | -187.215% |
| TheraVet SA | -1.57 Million EUR | -1247.291% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -4.021% |
| argenx SE | -272.91 Million EUR | 92.246% |
| BioSenic S.A. | -28.77 Million EUR | 26.465% |
| Celyad Oncology SA | -8.44 Million EUR | -150.497% |
| DBV Technologies S.A. | -67.26 Million EUR | 68.541% |
| Galapagos NV | 211.69 Million EUR | 109.996% |
| Genfit S.A. | -28.89 Million EUR | 26.76% |
| GeNeuro SA | -14.75 Million EUR | -43.403% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -37.594% |
| Innate Pharma S.A. | -7.57 Million EUR | -179.551% |
| Inventiva S.A. | -110.42 Million EUR | 80.836% |
| MaaT Pharma SA | -19.71 Million EUR | -7.329% |
| MedinCell S.A. | -25.03 Million EUR | 15.48% |
| Nanobiotix S.A. | -39.7 Million EUR | 46.695% |
| Onward Medical N.V. | -36.18 Million EUR | 41.511% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -531.147% |
| OSE Immunotherapeutics SA | -23 Million EUR | 8.003% |
| Oxurion NV | -18.96 Million EUR | -11.561% |
| Pharming Group N.V. | -9.75 Million EUR | -116.9% |
| Poxel S.A. | -35.09 Million EUR | 39.692% |
| GenSight Biologics S.A. | -26.22 Million EUR | 19.291% |
| Transgene SA | -22.32 Million EUR | 5.222% |
| Financière de Tubize SA | 88.15 Million EUR | 124.006% |
| UCB SA | 343 Million EUR | 106.17% |
| Valneva SE | -101.42 Million EUR | 79.136% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 25.333% |